AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00264199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: iv. by weight (1.0 pmol/kg/min )
Study NCT00264199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same rate of infusion as GLP-1
Study NCT03715803 — intervention group
Intervention type: DEVICE
Intervention: Calistar A mesh to treat anterior and apical POP
Description: Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
Study NCT03715803 — intervention group
Intervention type: DEVICE
Intervention: Calistar S mesh to treat anterior and apical POP
Description: Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
Study NCT00717249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyifilcon A control lens
Description: Marketed daily wear contact lens
Study NCT00717249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galyfilcon A with a silver additive
Description: Investigational daily wear contact lens
Study NCT01102036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cultura L casei F19, acidophilus La5 , B lactis Bb 12
Description: 2 weeks consumption,250 ml/day
Study NCT01102036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt without probiotics
Description: Yoghurt without probiotics
Study NCT03169335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1101
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Study NCT03169335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Study NCT03169335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
Study NCT00530621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
Study NCT00530621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study NCT01424553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevention and follow-up of the patients pulmonary parameters
Description: Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
Study NCT02371499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG
Description: the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
Study NCT02371499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
Study NCT00000439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium valproate
Description: subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
Study NCT00530621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
Study NCT00530621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
Study NCT01646268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period
Study NCT01646268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches
Study NCT02753582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SOD+Gliadin Capsule
Study NCT02753582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03690375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broad Band Light (BBL)
Description: Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
Study NCT04327869 — intervention group
Intervention type: DEVICE
Intervention: Magnetically controlled capsule endoscopy
Description: The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
Study NCT03913429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration
Description: Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml
Study NCT03913429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary nerve blockade
Description: Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF.
Study NCT02908191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Study NCT03169335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
Study NCT03169335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
Study NCT03169335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
Study NCT04469972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
Study NCT02908191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Study NCT02908191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Used to treat adults with chronic hepatitis B virus
Study NCT02908191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Used to treat adults with chronic hepatitis B virus
Study NCT02908191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Used to treat adults with chronic hepatitis B virus who show signs of liver damage
Study NCT02908191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide
Description: Used to treat adults with chronic hepatitis B virus
Study NCT03414099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketum
Description: Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
Study NCT03414099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink matched for taste and appereance
Study NCT04190251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inteprofessional medication adherence support program (IMAP)
Description: In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
Study NCT03998696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 40 mg/m2
Description: Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
Study NCT03998696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2
Description: Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
Study NCT02775409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous placement
Description: The tissue expander will be placed above the muscle.
Study NCT02775409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submuscular placement
Description: The tissue expander will be placed below the muscle
Study NCT02424357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5%povidone iodine ophthalmic solution
Description: one drop of 5% povidone iodine instilled into the conjunctival fornix.
Study NCT02424357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine post-operative ophthalmic ointment
Description: patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
Study NCT02424357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine post-operative ophthalmic ointment
Description: patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
Study NCT01977924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one month polyphenols supplementation (600mg)
Study NCT01977924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (microcrystalline cellulose)
Study NCT02259166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHFP+
Description: Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
Description: Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Azelaic Acid Cream
Description: Azelaic Acid Cream 20%
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Metronidazole gel
Description: Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Metronidazole cream
Description: Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Metronidazole Emulsion
Description: Metronidazole Emulsion 0.75%
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Metronidazole Lotion
Description: Metronidazole Lotion 0,75%
Study NCT02602470 — intervention group
Intervention type: DRUG
Intervention: Brimonidine Tartrate Gel
Description: Brimonidine Tartrate Gel 0.33%
Study NCT03250611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipital Condyle Screw
Description: Occipito-Cervical Screw-Rod Fixation Technique
Study NCT01351324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Absence or presence of fish oil
Description: Oral dose of saturated fat with or without fish oil and a heparin infusion
Study NCT00000439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium valproate
Description: subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
Study NCT03130556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
Study NCT01302392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
Study NCT01302392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).
Study NCT03130556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat, High Calorie Meal
Description: A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
Study NCT03130556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
Study NCT03914417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% Cream
Description: Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
Study NCT02021669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Description: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
Study NCT02021669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Study NCT01597336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator abscess flush
Description: Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
Study NCT01597336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline flush of abscess
Description: Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
Study NCT02956694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional e-learning program on shared decision making
Description: Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
Study NCT00154297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Study NCT00154297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (RAD001)
Study NCT04348799 — intervention group
Intervention type: OTHER
Intervention: BPD
Description: It is a observation research.we didn't intervene anything.
Study NCT02581826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silodosin
Description: α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
Study NCT02581826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No column specified.
Study NCT04271254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
Study NCT02043015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Condom choices
Description: Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Study NCT02043015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Condom-compatible lubricant choices
Description: Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Study NCT02043015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couples HIV counseling and testing (CVCT)
Description: Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
Study NCT02043015 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pre-exposure prophylaxis with FTC/TDF
Description: For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
Study NCT02043015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Staff and provider MSM and LGBT sensitization training
Description: The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
Study NCT02043015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HIV Testing and Risk-reduction counseling
Description: Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
Study NCT02043015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Linkage to care
Description: Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.